# Efficacy and Safety of LAS 34273 in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease(COPD)

> **NCT00358436** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 804 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease (COPD)

## Interventions

- **DRUG:** Aclidinium bromide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00358436
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2008-06
- **Final completion:** 2008-06
- **Target enrollment:** 804 (ACTUAL)
- **Last updated:** 2017-01-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00358436

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00358436, "Efficacy and Safety of LAS 34273 in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease(COPD)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00358436. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*